文献速递脑血管病神经重症与神经感染

急性缺血性卒中伴已形成大面积梗死行血管内取栓(TENSION):多中心、开放标签、随机试验的12个月结局

Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial.
PubMed 文献 · Lancet Neurol · 2024-07-26

TENSION试验在40家欧洲医院和1家加拿大医院纳入前循环大血管闭塞、ASPECTS 3-5分的急性缺血性卒中患者,随机接受血管内取栓联合药物治疗或单纯药物治疗。12个月随访显示,取栓组改良Rankin量表评分分布向更好功能结局偏移(调整共同比值比2.39,95%CI 1.47-3.90),生活质量更优,总生存略好(调整风险比0.70,95%CI 0.50-0.99)。

要点

  • 取栓组12个月mRS评分分布向更好功能结局偏移,调整共同OR 2.39(95%CI 1.47-3.90)。
  • 取栓组EQ-5D指数中位数0.7 vs 单纯药物组0.4,生活质量更优。
  • 取栓组总生存略优于单纯药物组,调整HR 0.70(95%CI 0.50-0.99)。

核心结论

  • 在急性缺血性卒中大血管闭塞伴已形成大面积梗死患者中,与单纯药物治疗相比,血管内取栓在卒中后12个月与更好的功能结局、生活质量和总生存相关。
  • 这些发现提示血管内取栓在大面积梗死缺血性卒中患者中的获益长期持续,并支持在这类患者中使用血管内取栓。

研究设计与样本

  • TENSION为开放标签、盲法终点、随机试验,在40家欧洲医院和1家加拿大医院进行。
  • 纳入年龄≥18岁、前循环大血管闭塞所致急性缺血性卒中且标准卒中影像ASPECTS 3-5分的大面积梗死患者。
  • 患者按1:1随机接受血管内取栓联合药物治疗或单纯药物治疗,治疗时间窗为卒中发作后12小时内。
  • 共随机分配253例患者,125例(49%)接受血管内取栓,128例(51%)接受单纯药物治疗;中位随访8.36个月(IQR 0.02-12.00)。

主要发现

  • 12个月时血管内取栓与mRS评分分布向更好功能结局偏移相关(调整共同OR 2.39,95%CI 1.47-3.90)。
  • EQ-5D指数中位数取栓组0.7(IQR 0.4-0.9)vs 单纯药物组0.4(IQR 0.2-0.7);EQ-5D视觉模拟量表健康状态中位数50(IQR 35-70)vs 30(IQR 5-60)。
  • PROMIS-10整体身体健康T评分中位数取栓组39.8(IQR 37.4-50.8)vs 单纯药物组37.4(IQR 32.4-44.9)。
  • PROMIS-10整体心理健康T评分中位数41.1(IQR 36.3-48.3)vs 38.8(IQR 31.3-44.7),组间差异证据不足;PHQ-4报告焦虑者13/58(22%)vs 15/36(42%),抑郁者18/58(31%)vs 18/36(50%),组间差异证据不足。
  • 总生存取栓组略优于单纯药物组(调整HR 0.70,95%CI 0.50-0.99)。

临床怎么用

  • 作者认为,在大面积梗死缺血性卒中患者中,血管内取栓的获益长期持续,并支持在这类患者中使用血管内取栓。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term data showing the benefits of endovascular thrombectomy for stroke with large infarct are scarce. The TENSION trial showed the safety and efficacy of endovascular thrombectomy in patients with ischaemic stroke and large infarct at 90 days. We aimed to investigate the safety and efficacy at 12 months of endovascular thrombectomy in patients who were enrolled in the TENSION trial. METHODS: TENSION was an open-label, blinded endpoint, randomised trial done at 40 hospitals across Europe and one hospital in Canada. We included patients (aged ≥18 years) with acute ischaemic stroke due to large vessel occlusion in the anterior circulation and who had a large infarct, as indicated by an Alberta Stroke Program Early Computed Tomographic Score (ASPECTS) of 3-5 on standard-of-care stroke imaging. We randomly assigned patients (1:1) to receive either endovascular thrombectomy with medical treatment or medical treatment only up to 12 h from stroke onset. The primary outcome was functional outcome across the entire range of the modified Rankin Scale at 90 days. Here, we report the prespecified 12-month follow-up analyses for functional outcome (using the simplified modified Rankin Scale questionnaire), quality of life (using the Patient-Reported Outcomes Measurement Information System 10-item [PROMIS-10] and EQ-5D questionnaires), post-stroke anxiety and depression (using the Patient Health Questionnaire-4 [PHQ-4]), and overall survival. Outcomes (except survival) were assessed in the intention-to-treat population; the survival analysis was based on treatment received. This trial is registered with ClinicalTrials.gov, NCT03094715, and is completed. FINDINGS: We enrolled patients between July 17, 2018, and Feb 21, 2023, when the trial was stopped early for efficacy. 253 patients were randomly assigned, 125 (49%) to endovascular thrombectomy and 128 (51%) to medical treatment only. Median follow-up was 8·36 months (IQR 0·02-12·00). Endovascular thrombectomy was associated with a shift in the distribution of scores on the modified Rankin Scale towards better functional outcome at 12 months (adjusted common odds ratio 2·39 [95% CI 1·47-3·90]). Endovascular thrombectomy was also associated with a better quality of life compared with medical treatment only, as reflected by median scores on the EQ-5D questionnaire index (0·7 [IQR 0·4-0·9] vs 0·4 [0·2-0·7]), median scores for health status on the EQ-5D questionnaire visual analogue scale (50 [IQR 35-70] vs 30 [5-60]), and median global physical health scores on the PROMIS-10 questionnaire (T-score 39·8 [IQR 37·4-50·8] vs 37·4 [32·4-44·9]); although there was not enough evidence to suggest a difference between groups in global mental health scores on PROMIS-10 (41·1 [IQR 36·3-48·3] vs 38·8 [31·3-44·7]) or the numbers of patients reporting anxiety (13 [22%] of 58 vs 15 [42%] of 36) and depression (18 [31%] vs 18 [50%]) on PHQ-4. Overall survival was slightly better in the endovascular thrombectomy group compared with medical treatment only (adjusted hazard ratio 0·70 [95% CI 0·50-0·99]). INTERPRETATION: In patients with acute ischaemic stroke from large vessel occlusion with established large infarct, compared with medical treatment only, endovascular thrombectomy was associated at 12 months after stroke with better functional outcome, quality of life, and overall survival. These findings suggest that the benefits of endovascular thrombectomy in patients with an ischaemic stroke and a large infarct are sustained in the long term and support the use of endovascular thrombectomy in these patients. FUNDING: European Union Horizon 2020 Research and Innovation Programme.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Thomalla G, Fiehler J, Subtil F, et al. Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial. Lancet Neurol. 2024. PMID: 39074480. doi:10.1016/S1474-4422(24)00278-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。